Clinical Trials Using Liposomal Cytarabine-Daunorubicin CPX-351

Clinical trials are research studies that involve people. The clinical trials on this list are studying Liposomal Cytarabine-Daunorubicin CPX-351. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-12 of 12
  • A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

    This study evaluates the pharmacokinetics and safety of CPX-351 in patients with moderate or severe renal impairment.
    Location: 4 locations

  • CPX-351 in Treating Patients with Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

    This phase I trial studies best dose and side effects of liposome-encapsulated daunorubicin-cytarabine (CPX-351) and how well it works in treating patients with high risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back or has not responded to treatment. Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ruxolitinib and CPX-351 in Treating Patients with Secondary Acute Myeloid Leukemia Transformed from Myeloproliferative Neoplasms

    This phase I / II trial studies the best dose of ruxolitinib when given together with CPX-351 and to see how well they work in treating patients with secondary acute myeloid leukemia transformed from myeloproliferative neoplasms. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. CPX-351 is a mixture of 2 chemotherapy drugs (daunorubicin and cytarabine) given for leukemia in small fat-based particles (liposomes) to improve the drug getting into cancer cells. Giving ruxolitinib and CPX-351 may work better in treating patients with secondary acute myeloid leukemia compared to CPX-351 alone.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • CPX-351 plus Enasidenib for Relapsed AML

    This trial evaluates how well CPX-351 and enasidenib work in treating patients with acute myeloid leukemia characterized by IHD2 mutation. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CPX-351 and enasidenib may work better in treating patients with acute myeloid leukemia, compared to giving only one of these therapies alone.
    Location: 4 locations

  • Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome

    This phase II trial studies the side effects and how well liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin work in treating patients with acute myeloid leukemia that has come back or that does not respond to treatment or high risk myelodysplastic syndrome. Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine and gemtuzumab ozogamicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants with Relapsed, Refractory or Untreated Acute Myeloid Leukemia

    This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine and venetoclax work in treating participants with acute myeloid leukemia that has come back, does not respond to treatment, or has not been treated. Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: M D Anderson Cancer Center, Houston, Texas

  • CPX-351 in Treating Patients with Acute Lymphoblastic Leukemia that has come back after prior therapy or does not respond to treatment

    This phase II trial studies how well CPX-351 works in treating patients with acute lymphoblastic leukemia that has come back or does not respond to treatment. CPX-351 is combination of two chemotherapy drugs called cytarabine and daunorubicin which are protected inside fat particles called liposomes to help prevent these drugs from being eliminated / destroyed by the body. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Liposome-Encapsulated Daunorubicin-Cytarabine in Treating Participants with Higher Risk Myelodysplastic Syndrome Who Are Transplant Eligible

    This phase I trial studies the side effects of liposome-encapsulated daunorubicin-cytarabine in treating participants with higher risk myelodysplastic syndrome who are transplant eligible. Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Cytarabine, Idarubicin and Liposome-encapsulated Daunorubicin-Cytarabine, or Venetoclax, Azacitidine, and Decitabine in Treating Older Patients with Acute Myeloid Leukemia

    This phase II trial studies how well cytarabine and idarubicin or venetoclax, azacitidine and decitabine work in treating patients with acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, idarubicin, liposome-encapsulated daunorubicin-cytarabine and venetoclax, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Azacitidine and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving patients cytarabine, idarubicin, liposome-encapsulated daunorubicin-cytarabine, venetoclax, azacitidine or decitabine may work better in treating patients with acute myeloid leukemia based on clinicogenetic risk stratification.
    Location: University of Nebraska Medical Center, Omaha, Nebraska

  • CPX-351 and Gemtuzumab Ozogamicin in Treating Patients with Relapsed Acute Myeloid Leukemia

    This phase Ib trial studies the best dose of gemtuzumab ozogamicin when given together with CPX-351 in treating patients with acute myeloid leukemia that has come back after it was previously in remission. CPX-351 is a type of chemotherapy. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzumab, linked to chemotherapy called calicheamicin. Gemtuzumab attaches to CD33 positive cancer cells in a targeted way and delivers ozogamicin to kill them. Giving CPX-351 and gemtuzumab ozogamicin may work better in treating patients with acute myeloid leukemia, compared to giving only one of these therapies alone.
    Location: 5 locations

  • CPX-351 and Palbociclib in Treating Patients with Recurrent or Refractory Acute Myeloid Leukemia

    This phase I / II trial studies the side effects and best dose of palbociclib when given together with CPX-351 and to see how well they work in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. The purpose of this study is to test the safety and efficacy of the combination of palbociclib plus CPX-351 in patients with acute myeloid leukemia.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio

  • A Post-Marketing Observational Study of VYXEOS™

    The purpose of this observational study is to provide data on the incidence and severity of infusion-related reactions during and immediately following each infusion of VYXEOS during the first induction.
    Location: 2 locations